Young‐Suk Lim

21.2k total citations · 1 hit paper
336 papers, 11.0k citations indexed

About

Young‐Suk Lim is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Young‐Suk Lim has authored 336 papers receiving a total of 11.0k indexed citations (citations by other indexed papers that have themselves been cited), including 292 papers in Hepatology, 237 papers in Epidemiology and 57 papers in Surgery. Recurrent topics in Young‐Suk Lim's work include Liver Disease Diagnosis and Treatment (186 papers), Hepatitis B Virus Studies (154 papers) and Hepatitis C virus research (144 papers). Young‐Suk Lim is often cited by papers focused on Liver Disease Diagnosis and Treatment (186 papers), Hepatitis B Virus Studies (154 papers) and Hepatitis C virus research (144 papers). Young‐Suk Lim collaborates with scholars based in South Korea, United States and Taiwan. Young‐Suk Lim's co-authors include Han Chu Lee, Kang Mo Kim, Ju Hyun Shim, Yung Sang Lee, Dong Jin Suh, Jonggi Choi, Seungbong Han, Jihyun An, Gi‐Ae Kim and Sung‐Gyu Lee and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Young‐Suk Lim

323 papers receiving 10.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion

2018 290 citations Sang Min Yoon, Baek‐Yeol Ryoo et al. profile →

Peers

Countries citing papers authored by Young‐Suk Lim

Since Specialization

Citations

This map shows the geographic impact of Young‐Suk Lim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Young‐Suk Lim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Young‐Suk Lim more than expected).

Fields of papers citing papers by Young‐Suk Lim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Young‐Suk Lim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Young‐Suk Lim. The network helps show where Young‐Suk Lim may publish in the future.

Co-authorship network of co-authors of Young‐Suk Lim

This figure shows the co-authorship network connecting the top 25 collaborators of Young‐Suk Lim. A scholar is included among the top collaborators of Young‐Suk Lim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Young‐Suk Lim. Young‐Suk Lim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma 2025 ·Alimentary Pharmacology & Therapeutics ·(unknown), (unknown), (unknown), Rex Wan‐Hin Hui, Byeong Geun Song, In Hye Song, (unknown), Tan To Cheung, Sung Won Chung, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young‐Suk Lim, Han Chu Lee, Wai‐Kay Seto, Jeong‐Hoon Lee, Won‐Mook Choi	0
2	Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment 2025 ·Alimentary Pharmacology & Therapeutics ·Grace Lai–Hung Wong, Edward Gane, Calvin Q. Pan, Scott Fung, Mang Ma, Namiki Izumi, S. Shalimar, Seng Gee Lim, Wan‐Long Chuang, (unknown), Young‐Suk Lim, Leland J. Yee, John F. Flaherty, (unknown), Hongyuan Wang, Marı́a Buti	0
3	Stereotactic body radiotherapy alone versus stereotactic body radiotherapy after incomplete transarterial therapy for hepatocellular carcinoma 2024 ·Journal of Medical Imaging and Radiation Oncology ·(unknown), Jinhong Jung, Jin‐hong Park, (unknown), Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young‐Suk Lim, Han Chu Lee, (unknown)	1
4	CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance 2024 ·Alimentary Pharmacology & Therapeutics ·Hye Won Lee, Terry Cheuk‐Fung Yip, Vincent Wai‐Sun Wong, Young‐Suk Lim, Henry Lik‐Yuen Chan, Sang Hoon Ahn, Grace Lai–Hung Wong, Jonggi Choi	4
5	Risk of Extrahepatic Malignancies in Patients With Autoimmune Hepatitis: A Nationwide Cohort Study 2024 ·The American Journal of Gastroenterology ·Sung Won Chung, Ye‐Jee Kim, (unknown), Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young‐Suk Lim, Han Chu Lee, Sehee Kim, Won‐Mook Choi	0
6	Are the New Nucleos(t)ide Analogs Better than the Old Nucleos(t)ide Analogs? 2023 ·Clinics in Liver Disease ·Jonggi Choi, Won‐Mook Choi, Young‐Suk Lim	1
7	Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks 2023 ·Alimentary Pharmacology & Therapeutics ·Scott Fung, Calvin Q. Pan, Grace Lai–Hung Wong, Wai‐Kay Seto, Sang Hoon Ahn, Chi‐Yi Chen, Hie‐Won Hann, Maciej Jabłkowski, Yoon Jun Kim, Cihan Yurdaydın, Cheng‐Yuan Peng, Tuan Nguyen, Hiroshi Yatsuhashi, John F. Flaherty, Leland J. Yee, (unknown), Hongyuan Wang, (unknown), Young‐Suk Lim, Marı́a Buti	7
8	Subclassification of advanced-stage hepatocellular carcinoma with macrovascular invasion: combined transarterial chemoembolization and radiotherapy as an alternative first-line treatment 2023 ·SHILAP Revista de lepidopterología ·(unknown), Won‐Mook Choi, Ju Hyun Shim, Danbi Lee, Kang Mo Kim, Young‐Suk Lim, Han Chu Lee, Jinhong Jung, Sang Min Yoon, Jonggi Choi	6
9	Stereotactic body radiation therapy for elderly patients with small hepatocellular carcinoma: a retrospective observational study 2022 ·SHILAP Revista de lepidopterología ·(unknown), Jinhong Jung, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young‐Suk Lim, Han Chu Lee, Jin‐hong Park, Sang Min Yoon	11
10	Abbreviated magnetic resonance imaging vs ultrasound for surveillance of hepatocellular carcinoma in high‐risk patients 2021 ·Liver International ·Hyo Jung Park, So Yeon Kim, Amit G. Singal, So Jung Lee, Hyung Jin Won, Jae Ho Byun, Sang Hyun Choi, Takeshi Yokoo, Minju Kim, Young‐Suk Lim	42
11	Radiologic Response as a Prognostic Factor in Advanced Hepatocellular Carcinoma with Macroscopic Vascular Invasion after Transarterial Chemoembolization and Radiotherapy 2021 ·Liver Cancer ·Jinhong Jung, Ji Hyeon Joo, So Yeon Kim, Jin Hyoung Kim, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young‐Suk Lim, Han Chu Lee, Jin‐hong Park, Sang Min Yoon	3
12	Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials 2021 ·Gut and Liver ·Jeong Heo, Yoon Jun Kim, Jin‐Woo Lee, (unknown), Young‐Suk Lim, Kwang‐Hyub Han, Sook‐Hyang Jeong, Mong Cho, Ki Tae Yoon, Si Hyun Bae, Eric D. Crown, Linda Fredrick, Negar Niki Alami, Armen Asatryan, (unknown), Seung Woon Paik, Youn Jae Lee	3
13	Role of Tumor Biomarkers in the Surveillance of Hepatocellular Carcinoma 2021 ·SHILAP Revista de lepidopterología ·Young‐Suk Lim	3
14	Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study 2021 ·Liver Cancer ·Changhoon Yoo, Jwa Hoon Kim, Min‐Hee Ryu, Sook Ryun Park, Danbi Lee, Kang Mo Kim, Ju Hyun Shim, Young‐Suk Lim, Han Chu Lee, Joycelyn Jie Xin Lee, David Tai, Stephen L. Chan, Baek‐Yeol Ryoo	68
15	Kinetics of the neutrophil‐lymphocyte ratio during PD‐1 inhibition as a prognostic factor in advanced hepatocellular carcinoma 2021 ·Liver International ·Won‐Mook Choi, Ji Yoon Kim, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Young‐Suk Lim, Han Chu Lee, Changhoon Yoo, Min‐Hee Ryu, Baek‐Yeol Ryoo, Kang Mo Kim	28
16	Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus–Related Hepatocellular Carcinoma After Surgical Resection 2020 ·Hepatology ·Jonggi Choi, (unknown), Young‐Suk Lim	77
17	Comparison of Long‐Term Clinical Outcomes Between Spontaneous and Therapy‐Induced HBsAg Seroclearance 2020 ·Hepatology ·Jonggi Choi, Sun Hong Yoo, Young‐Suk Lim	21
18	High level of medication adherence is required to lower mortality in patients with chronic hepatitis B taking entecavir: A nationwide cohort study 2020 ·Journal of Viral Hepatitis ·Jayoun Lee, Songhee Cho, Hyo Jeong Kim, (unknown), Min Jung Ko, Young‐Suk Lim	13
19	Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health‐related quality of life in East Asian patients with hepatitis C virus infection 2018 ·Journal of Viral Hepatitis ·Zobair M. Younossi, Maria Stepanova, Linda Henry, Kwang‐Hyub Han, Sang Hoon Ahn, Young‐Suk Lim, Wan‐Long Chuang, Jia‐Horng Kao, Kinh Van Nguyen, Ching‐Lung Lai, Henry Lik‐Yuen Chan, Lai Wei	14
20	The effect of interferon‐free regimens on health‐related quality of life in East Asian patients with chronic hepatitis C 2017 ·Liver International ·Zobair M. Younossi, Maria Stepanova, Linda Henry, Kwang‐Hyub Han, Sang Hoon Ahn, Young‐Suk Lim, Wan‐Long Chuang, Jia‐Horng Kao, (unknown), Ching‐Lung Lai, Man‐Fung Yuen, Henry Lik‐Yuen Chan, Lai Wei	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact